XORTX Therapeutics (XRTX) Net Equity Issued and Repurchased (2020 - 2025)

XORTX Therapeutics' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $1.1 million for Q4 2025.

• Quarterly Net Equity Issued and Repurchased fell 26.5% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 million (down 35.57% YoY) and the FY2025 annual result came in at $2.3 million, down 35.57% from the prior year.
• Net Equity Issued and Repurchased was $1.1 million for Q4 2025 at XORTX Therapeutics, up from $1.0 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $13.2 million in Q4 2021 and bottomed at $113547.0 in Q1 2025.
• A 3-year average of $3.4 million and a median of $1.5 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased surged 1187.32% — and 2025, when it tumbled 94.32%.
• XORTX Therapeutics' Net Equity Issued and Repurchased stood at $13.2 million in 2021, then plunged by 88.66% to $1.5 million in 2024, then retreated by 26.5% to $1.1 million in 2025.
• Business Quant data shows XRTX's Net Equity Issued and Repurchased at $1.1 million in Q4 2025, $1.0 million in Q3 2025, and $113547.0 in Q1 2025.